Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
There is some good news and bad news for fans of Cathie Wood. The good news for the co-founder CEO of the Ark Invest family of exchange-traded funds (ETFs) is that her largest fund -- with more than $9 billion in assets -- is rolling in 2023. It's up 40% so far this year, more than doubling the market's healthy return. After sliding badly in 2021 and 2022, Wood is back on top.
The bad news is that she's not all the way back on top. The ETF is still 73% below its all-time high set in early 2021. It's also retreated 15% from its recent summertime high.
She's making moves to get back on top. What's she buying? Wood added to her existing stakes in Palantir Technologies (NYSE: PLTR), Intellia Therapeutics (NASDAQ: NTLA), and Accolade (NASDAQ: ACCD) on Thursday. Let's take a closer look.
Source Fool.com
Intellia Therapeutics Inc Stock
We see a rather positive sentiment for Intellia Therapeutics Inc with 15 Buy predictions and 1 Sell predictions.
Based on the current price of 22.65 € the target price of 60 € shows a potential of 164.9% for Intellia Therapeutics Inc which would more than double the current price.
